Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer
Chen, Yungchang, Li, Xiaoqian, Yuxin, Man, Hu, Hai, Wang, Liyang, Zhang, Zhixuan, Chen, Ping, Liu, Yang, Lu, Jin, Lin, Tongyu
Published in Journal of clinical oncology (01.02.2023)
Published in Journal of clinical oncology (01.02.2023)
Get full text
Journal Article
Identifying SLC2A6 as the novel protective factor in breast cancer by TP53-related genes affecting M1 macrophage infiltration
Dai, Chao, Man, Yuxin, Zhang, Luhan, Zhang, Xiao, Xie, Chunbao, Wang, Shan, Zhang, Yinjie, Guo, Qian, Zou, Liang, Hong, Huangming, Jiang, Lingxi, Shi, Yi
Published in Apoptosis (London) (01.08.2024)
Published in Apoptosis (London) (01.08.2024)
Get full text
Journal Article
A phase ib-II study of dabrafenib, trametinib, cetuximab plus irinotecan in patients with BRAF mutant metastatic colorectal cancer: Subgroup analysis and biomarker identification
Chen, Yungchang, Hu, Hai, Song, Bo, Shang, Jin, Man, Yuxin, Guo, Qian, Yuan, Hongfan, Rui, Yuanyi, Deng, Zijian, Pan, Tao, Yi, Bo, Zhang, Zhixuan, Chen, Ping, Lu, Jin, Zhong, Deyuan, Lin, Tongyu
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Application of SLC2A6 as therapeutic target and screening target and breast cancer screening kit
REN WEIMING, JIANG LINGXI, SHI YI, DAI CHAO, LI QI, MAN YUXIN, WANG XINYU, LIU JIANXIN
Year of Publication 19.09.2023
Get full text
Year of Publication 19.09.2023
Patent
Application of reagent for inhibiting NAT9 gene expression
REN WEIMING, JIANG LINGXI, MIAO YANGBAO, SHI YI, DAI CHAO, LI QI, MAN YUXIN, WANG XINYU, XIE CHUNBAO, LIU JIANXIN
Year of Publication 12.09.2023
Get full text
Year of Publication 12.09.2023
Patent